Advances in molecular diagnostics have led to growing interest in liquid biopsy as a minimally invasive approach for cancer detection and monitoring. Unlike traditional tissue biopsy, liquid biopsy analyses tumor-derived components such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and tumor-derived extracellular vesicles present in blood or other body fluids. This technology offers the potential to detect malignancy through a simple blood test, enabling earlier diagnosis, real-time disease monitoring, and assessment of treatment response.
In recent years, liquid biopsy has shown promise in identifying genetic alterations associated with several cancers, including lung, colorectal, breast, and prostate malignancies. Multi-cancer early detection (MCED) assays using ctDNA methylation patterns are being investigated as tools for screening asymptomatic individuals,…
